UK Committee Urges Clarity On No-Deal Brexit Medicine Supplies
Executive SummaryA parliamentary committee has called on the health department to provide more clarity as to how it plans to ensure continuity of medicine supplies in the event of a no-deal Brexit. At the same time, the government has produced a set of draft regulations allowing the UK MHRA to take over drug regulatory functions currently performed at EU level.
You may also be interested in...
The BioIndustry Association wants the government to rule out a “no-deal” Brexit, saying it would be bad for patients and the life sciences sector.
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.